Last reviewed · How we verify
TYSABRI and AVONEX
TYSABRI blocks α4-integrin to prevent immune cells from crossing the blood-brain barrier, while AVONEX is interferon beta-1a that modulates immune response; together they reduce inflammation in multiple sclerosis.
TYSABRI blocks α4-integrin to prevent immune cells from crossing the blood-brain barrier, while AVONEX is interferon beta-1a that modulates immune response; together they reduce inflammation in multiple sclerosis. Used for Relapsing-remitting multiple sclerosis (TYSABRI), Clinically isolated syndrome suggestive of multiple sclerosis (AVONEX), Relapsing multiple sclerosis (AVONEX).
At a glance
| Generic name | TYSABRI and AVONEX |
|---|---|
| Sponsor | Biogen |
| Drug class | Monoclonal antibody (TYSABRI); Interferon (AVONEX) |
| Target | α4-integrin (TYSABRI); Interferon-beta receptor (AVONEX) |
| Modality | Small molecule |
| Therapeutic area | Immunology / Neurology |
| Phase | FDA-approved |
Mechanism of action
TYSABRI (natalizumab) is a monoclonal antibody that binds α4-integrin on lymphocytes, preventing their adhesion to vascular endothelium and migration into the central nervous system. AVONEX (interferon beta-1a) enhances immunoregulatory cytokine production and reduces pro-inflammatory responses. These are typically used sequentially or as part of combination therapy strategies in MS management.
Approved indications
- Relapsing-remitting multiple sclerosis (TYSABRI)
- Clinically isolated syndrome suggestive of multiple sclerosis (AVONEX)
- Relapsing multiple sclerosis (AVONEX)
Common side effects
- Progressive multifocal leukoencephalopathy (PML)
- Infusion reactions
- Headache
- Fatigue
- Flu-like symptoms (AVONEX)
- Injection site reactions (AVONEX)
Key clinical trials
- Traditional Versus Early Aggressive Therapy for Multiple Sclerosis Trial (NA)
- Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS (PHASE4)
- Pregnancy Exposure Registry for Vumerity (Diroximel Fumarate)
- A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a (PHASE4)
- Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study (PHASE2)
- Study Evaluating Rebif, Copaxone, and Tysabri for Active Multiple Sclerosis (PHASE3)
- Treatment Interruption of Natalizumab (PHASE2)
- Analysis of Lymphocyte Cell Surface Adhesion Marker Expression in Natalizumab Population With Active Control
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TYSABRI and AVONEX CI brief — competitive landscape report
- TYSABRI and AVONEX updates RSS · CI watch RSS
- Biogen portfolio CI